Core Viewpoint - BrainsWay Ltd. will report its fourth quarter and full year 2025 financial results on March 11, 2026, and will host a conference call to discuss these results and provide updates on business operations [1]. Group 1: Financial Reporting - The financial results will be announced before the U.S. financial markets open on March 11, 2026 [1]. - A conference call and webcast will take place at 8:30 AM Eastern Time to discuss the results [1]. Group 2: Conference Call Details - The conference call can be accessed in the U.S. at 1-877-300-8521 and internationally at 1-412-317-6026 [2]. - The conference ID for the call is 10206784, and it will be available for replay for 30 days on the Company's website [2]. Group 3: Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [3]. - The company has obtained three FDA-cleared indications for its treatments, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [3]. - Founded in 2003, BrainsWay operates in the U.S. and Israel and is focused on increasing awareness and access to Deep TMS [3].

Core Viewpoint - BrainsWay Ltd. has announced that Premera Blue Cross Blue Shield has adopted a new medical policy expanding coverage for patients aged 15 and older with moderate to severe major depressive disorder treated with BrainsWay's SWIFT Deep TMS protocol, marking a significant development in insurance coverage for this treatment [1][2]. Group 1: Company Developments - The SWIFT depression protocol consists of five treatment sessions per day for six days, followed by two sessions per day once a week for four weeks, totaling 38 sessions, and does not require expensive neuronavigational equipment [3]. - BrainsWay's clinical trials and real-world evidence show comparable response and remission outcomes for the SWIFT protocol compared to the standard Deep TMS protocol, indicating its effectiveness [4]. - The company continues to lead in the field with its proprietary H-coil technology and is focused on expanding access to advanced neurostimulation therapies through collaboration with providers and policymakers [5]. Group 2: Company Background - BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, with a proprietary Deep TMS platform that has received FDA clearance for multiple indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [6]. - The company was founded in 2003 and operates in the United States and Israel, with ongoing clinical trials for various psychiatric, neurological, and addiction disorders [6].

Core Insights - BrainsWay Ltd. achieved record quarterly sales of $11.4 million in Q4 2024, marking a 27% increase compared to Q4 2023 [1][4] - The full year 2024 revenue rose nearly 30% year-over-year to $41 million [1][4] - The company exceeded its full year 2024 operating income and Adjusted EBITDA margin guidance [1] - For 2025, BrainsWay expects continued strong growth, projecting revenue between $49 million and $51 million, indicating a growth of 20% to 24% over 2024 [1][10] Q4 2024 Financial Highlights - Q4 2024 revenue was $11.4 million, a 27% increase from Q4 2023 [4] - A total of 75 Deep TMS™ systems were shipped, a 25% increase from the previous year [4] - Gross margin for Q4 2024 remained at 75%, consistent with the prior year [4] - Operating income for Q4 2024 was $0.4 million, up from $0.2 million in Q4 2023 [4] - Adjusted EBITDA for Q4 2024 was approximately $1.4 million, compared to $0.8 million in Q4 2023 [4] - Net income for Q4 2024 was $1.5 million, significantly higher than $0.1 million in Q4 2023 [4] Full Year 2024 Financial Highlights - Full year 2024 revenue reached $41 million, a 29% increase from 2023 [4] - Gross margin for the full year was 75%, slightly up from 74% in the previous year [4] - Operating income for the full year was $1.4 million, a turnaround from a loss of $5 million in 2023 [4] - Net income for the full year was $2.9 million, compared to a net loss of $4.2 million in 2023 [4] - Adjusted EBITDA for the full year was approximately $4.5 million, compared to an adjusted EBITDA loss of $2.4 million in the prior year [4] Strategic Developments - The company completed a $20 million strategic equity financing transaction with Valor Equity Partners [4] - As of December 31, 2024, cash and cash equivalents totaled $69.4 million, a significant increase from $10.5 million in 2023 [4][19] - BrainsWay received expanded FDA labeling for Deep TMS to treat late-life depression, broadening the age range for treatment [4] - The company reported a significant increase in Deep TMS treatments for anxious depression in the second half of 2024, addressing a large medical condition affecting millions in the U.S. [4] 2025 Financial Guidance - BrainsWay anticipates revenue for 2025 to be between $49 million and $51 million, representing a growth of 20% to 24% over 2024 [10] - The company targets an operating income of 3% to 4% and an Adjusted EBITDA of 11% to 12% for the full year 2025 [10]